ペグビソマント
Sign in to saveAlso known as GH-N, Growth hormone, GH, Pituitary growth hormone, Somatotropin precursor, Growth hormone 1, B2036-PEG
Pegvisomant, sold under the brand name Somavert, is a growth hormone receptor antagonist used in the treatment of acromegaly. It is primarily used if the pituitary gland tumor causing the acromegaly cannot be controlled with surgery or radiation, and the use of somatostatin analogues is unsuccessful, but is also effective as a monotherapy. It is delivered as a powder that is mixed with water and injected under the skin.
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Protein
- First approval
- 2002
- Admin. routes
- parenteral
- Indications
- acromegaly, prostate adenocarcinoma, sarcoma, breast neoplasm
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 3 more facts
- medical condition treated
- acromegaly
- defined daily dose
- 10.0
- has characteristic
- biopharmaceutical
via Wikidata · CC0
Article · 日本語
ペグビソマント(Pegvisomant)は、先端巨大症の治療に使用される成長ホルモン受容体拮抗薬である。先端巨大症の原因である下垂体腫瘍を手術や放射線治療で制御できない場合に使用される。主にソマトスタチンアナログの使用で効果が得られない場合に用いられるが、単剤投与でも有効である。皮下注射で投与される。
Abstract from DBpedia / Wikipedia · CC BY-SA
Available in 16 languages
- Español
- Français
- Deutsch
- 日本語
- Português
- Italiano
- العربية
- Macedonian
- Odia
- Polski
- Serbian
- Serbian (Latin)
- Slovenian
- Tiếng Việt
- Ukrainian
via Wikidata sitelinks · CC0